Enhancement of the Inhibitory Activity of oatp Antisense Oligonucleotides by Incorporation of 2′-O,4′-C-Ethylene-Bridged Nucleic Acids (ENA) without a Loss of Subtype Selectivity

Biochemistry

Volumn 43, Issue 15, 2004, Pages 4501-4510

  Takagi, Miho ^a   Morita, Koji ^a   Nakai, Daisuke ^a   Nakagomi, Rie ^a   Tokui, Taro ^a   Koizumi, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; ENZYMES; GENES; NEGATIVE IONS; POLYPEPTIDES; RNA;

ANTISENSE IN VITRO SELECTION (AIVS); ANTISENSE OLIGONUCLEOTIDES (AON); GENE ALIGNMENT PROGRAM (GAP); ORGANIC ANION TRANSPORTING POLYPEPTIDE (OATP);

BIOCHEMISTRY;

ANTISENSE OLIGONUCLEOTIDE; ETHYLENE DERIVATIVE; RIBONUCLEASE H;

ANIMAL CELL; ARTICLE; GENE TARGETING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALS; BASE SEQUENCE; BIOLOGICAL TRANSPORT; BRIDGED COMPOUNDS; ETHYLENES; GENE TARGETING; KIDNEY; LIVER; MOLECULAR SEQUENCE DATA; NUCLEOSIDES; OLIGONUCLEOTIDES, ANTISENSE; OOCYTES; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; RATS; SEQUENCE ALIGNMENT; THIONUCLEOTIDES; XENOPUS LAEVIS;

ANIMALIA; ENA; XENOPUS LAEVIS;

EID: 16544383519     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi035847x     Document Type: Article

References (45)

1. Kurreck, J. (2003) Antisense technologiesm, Eur. J. Biochem. 270, 1628-1644.
2. Bennett, C. F., and Cowsert, L. M. (1999) Antisense oligonucleotides as a tool for gene functionalization and target validation, Biochim. Biophys. Acta 1489, 19-30.
3. Kennewell, P. (2003) Technology evaluation: ISIS-104838, Curr. Opin. Mol. Ther. 5, 76-80.
4. Geary, R. S., Henry, S. P., and Grillone, L. R. (2002) Fomivirsen: clinical pharmacology and potential drug interactions, Clin. Pharmacokinet. 41, 255-260.
5. Patzel, V., Steidl, U., Kronenwett, R., Haas, R., and Sczakiel, G. (1999) A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability, Nucleic Acids Res. 27, 4328-4334.
6. Mathews, D. H., Sabina, J., Zuker, M., and Turner, D. H. (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure, J. Mol. Biol. 288, 911-940.
7. Bruice, T. W., and Lima, W. F. (1997) Control of complexity constraints on combinatorial screening for preferred oligonucleotide hybridization sites on structured RNA, Biochemistry 36, 5004-5019.
8. Ho, S. P., Britton, D. H., Stone, B. A., Behrens, D. L., Leffet, L. M., Hobbs, F. W., Miller, J. A., and Trainor, G. L. (1996) Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries, Nucleic Acids Res. 24, 1901-1907.
9. Lloyd, B. H., Giles, R. V., Spiller, D. G., Grzybowski, J., Tidd, D. M., and Sibson, D. R. (2001) Determination of optimal sites of antisense oligonucleotide cleavage within TNFα mRNA, Nucleic Acids Res. 29, 3664-3673.
10. Sohail, M., Hochegger, H., Klotzbucher, A., Guellec, R. L., Hunt, T., and Southern, E. M. (2001) Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo, Nucleic Acids Res. 29, 2041-2051.
11. Freier, S. M., and Altmann, K. H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes, Nucleic Acids Res. 25, 4429-4443.
12. Monia, B. P., Johnson, J. F., Sasmor, H., and Cummins, L. L. (1996) Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras, J. Biol. Chem. 271, 14533-14540.
13. Zhang, H., Cook, J., Nickel, J., Yu, R., Stecker, K., Myers, K., and Dean, N. M. (2000) Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis, Nat. Biotechnol. 18, 862-867.
14. Agrawal, S., Kandimalla, E. R., Yu, D., Ball, R., Lombardi, G., Lucas, T., Dexter, D. L., Hollister, B. A., and Chen, S. F. (2002) GEM 231, a second-generation antisense agent complementary to protein kinase A RIα subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer, Int. J. Oncol. 21, 65-72.
15. Obika, S., Nanbu, D., Hari, Y., Morio, K., In, Y., Ishida, T., and Imanishi, T. (1997) Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering, Tetrahedron Lett. 38, 8735-8738.
16. Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., and Wengel, J. (1998) LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition, Tetrahedron 54, 3607-3630.
17. Obika, S., Uneda, T., Sugimoto, T., Nanbu, D., Minami, T., Doi, T., and Imanishi, T. (2001) 2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties, Bioorg. Med. Chem. 9, 1001-1011.
18. Braasch, D. A., and Corey, D. R. (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA, Chem. Biol. 8, 1-7.
19. Morita, K., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., and Koizumi, M. (2002) 2′-O,4′-C-Ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug, Bioorg. Med. Chem. Lett. 12, 73-76.
20. Morita, K., Takagi, M., Hasegawa, C., Kaneko, M., Tsutsumi, S., Sone, J., Ishikawa, T., Imanishi, T., and Koizumi, M. (2003) Synthesis and properties of 2′-O,4′-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides, Bioorg. Med. Chem. 11, 2211-2226.
21. Hagenbuch, B., and Meier, P. J. (2003) The superfamily of organic anion transporting polypeptides, Biochim. Biophys. Acta 1609, 1-18.
22. +-independent organic anion transporter, Proc. Natl. Acad. Sci. U.S.A. 91, 133-137.
23. Abe, T., Kakyo, M., Sakagami, H., Tokui, T., Nishio, T., Tanemoto, M., Nomura, H., Hebert, S. C., Matsuno, S., Kondo, H., and Yawo, H. (1998) Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2, J. Biol. Chem. 273, 22395-22401.
24. Hotoda, H., Koizumi, M., Koga, R., Momota, K., Ohmine, T., Furukawa, H., Nishigaki, T., Kaneko, M., Kimura, S., and Shimada, K. (1996) Biologically active oligodeoxyribonucleotides. IV. Anti-HIV-1 activity of TGGGAG having hydrophobic substituent at its 5′-end via phosphodiester linkage, Nucleosides Nucleotides 15, 531-538.
25. Koizumi, M., Koga, R., Hotoda, H., Momota, K., Ohmine, T., Furukawa, H., Agatsuma, T., Nishigaki, T., Abe, K., Kosaka, T., Tsutsumi, S., Sone, J., Kaneko, M., Kimura, S., and Shimada, K. (1997) Biologically active oligodeoxyribonucleotides. IX. Synthesis and anti-HIV-1 activity of hexadeoxyribonucleotides, TGGGAG, bearing 3′- and 5′ -end-modification, Bioorg. Med. Chem. 5, 2235-2243.
26. Iyer, R. P., Phillips, L. R., Egan, W., Regan, J. B., and Beaucage, S. L. (1990) The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent, J. Org. Chem. 55, 4693-4699.
27. Koizumi, M., and Breaker, R. R. (2000) Molecular recognition of cAMP by an RNA aptamer, Biochemistry 39, 8983-8992.
28. Inoue, H., Hayase, Y., Iwai, S., and Ohtsuka, E. (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H, FEBS Lett. 215, 327-330.
29. Saenger, W. (1984) Principles of nucleic acid structure, Springer-Verlag, New York.
30. Ehresmann, C., Baudin, F., Mougel, M., Romby, P., Ebel, J. P., and Ehresmann, B. (1987) Probing the structure of RNAs in solution, Nucleic Acids Res. 15, 9109-9128.
31. Osborne, S. E., and Ellington, A. D. (1997) Nucleic acid selection and the challenge of combinatorial chemistry, Chem. Rev. 97, 349-370.
32. Breaker, R. R. (1997) In vitro selection of catalytic polynucleotides, Chem. Rev. 97, 371-390.
33. Morita, K., Yamate, K., Kurakata, S., Abe, K., Imanishi, T., and Koizumi, M. (2002) Downregulation of VEGF mRNA expression by 2′-O,4′ -C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression, Nucleic Acids Res. 2 (Suppl.), 99-100.
34. Kurreck, J., Wyszko, E., Gillen, C., and Erdmann, V. A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids, Nucleic Acids Res. 30, 1911-1918.
35. Wagner, R. W., Matteucci, M. D., Grant, D., Huang, T., and Froehler, B. C. (1996) Potent and selective inhibition of gene expression by an antisense heptanucleotide, Nat. Biotechnol. 14, 840-844.
36. He, G. X., Williams, J. P., Postich, M. J., Swaminathan, S., Shea, R. G., Terhorst, T., Law, V. S., Mao, C. T., Sueoka, C., Coutre, S., and Bischofberger, N. (1998) In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages, J. Med. Chem. 41, 4224-4231.
37. Burgin, A. B., Jr., Gonzalez, C., Matulic-Adamic, J., Karpeisky, A. M., Usman, N., McSwiggen, J. A., and Beigelman, L. (1996) Chemically modified hammerhead ribozymes with improved catalytic rates, Biochemistry 35, 14090-14097.
38. Toledo, L. M., Lydon, N. B., and Elbaum, D. (1999) The structure-based design of ATP-site directed protein kinase inhibitors, Curr. Med. Chem. 6, 775-805.
39. Szczepankiewicz, B. G., Liu, G., Hajduk, P. J., Abad-Zapatero, C., Pei, Z., Xin, Z., Lubben, T. H., Trevillyan, J. M., Stashko, M. A., Ballaron, S. J., Liang, H., Huang, F., Hutchins, C. W., Fesik, S. W., and Jirousek, M. R. (2003) Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy, J. Am. Chem. Soc. 125, 4087-4096.
40. Dean, N. M., and McKay, R. (1994) Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides, Proc. Natl. Acad. Sci. U.S.A. 91, 11762-11766.
41. Butler, M., McKay, R. A., Popoff, I. J., Gaarde, W. A., Witchell, D., Murray, S. F., Dean, N. M., Bhanot, S., and Monia, B. P. (2002) Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice, Diabetes 51, 1028-1034.
42. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., and Jirousek, M. R. (2002) PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice, Proc. Natl. Acad. Sci. U.S.A. 99, 11357-11362.
43. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., Ossipov, M., Koshkin, A., Jakobsen, N., Skouv, J., Oerum, H., Jacobsen, M. H., and Wengel, J. (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids, Proc. Natl. Acad. Sci. U.S.A. 97, 5633-5638.
44. Levin, A. A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides, Biochim. Biophys. Acta 1489, 69-84.
45. Nicklin, P. L., Bayley, D., Giddings, J., Craig, S. J., Cummins, L. L., Hastewell, J. G., and Phillips, J. A. (1998) Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes, Pharm. Res. 15, 583-591.